Yamamoto Akira, Toiyama Yuji, Okugawa Yoshinaga, Oki Satoshi, Ide Shozo, Saigusa Susumu, Araki Toshimitsu, Kusunoki Masato
Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Mie, Japan.
Dis Colon Rectum. 2019 Feb;62(2):171-180. doi: 10.1097/DCR.0000000000001245.
Despite advances in local control of rectal cancer, recurrence in distant organs is still one of the main causes of mortality. Prognostic biomarkers would be valuable for the treatment of patients who have rectal cancer.
The aim of our study was to investigate the prognostic impact of lymphocyte-to-monocyte ratio in patients with rectal cancer receiving preoperative chemoradiotherapy, and to clarify the clinical significance of lymphocyte-to-monocyte ratio.
Prospectively maintained data of patients with rectal cancer were retrospectively evaluated to clarify the clinical relevance of the lymphocyte-to-monocyte ratio.
This study was conducted at a single expert center.
A total of 119 consecutive patients with rectal cancer through chemoradiotherapy followed by total mesorectal excision at our institute were enrolled in this study. Eight patients were excluded because of a lack of laboratory data, and finally 111 patients were assessed in this study.
The primary outcome measured was the clinical relevance of the lymphocyte-to-monocyte ratio in patients with rectal cancer receiving chemoradiotherapy.
Patients with a low pretreatment lymphocyte-to-monocyte ratio showed poor prognosis significantly both in overall survival and disease-free survival of those with rectal cancer receiving chemoradiotherapy. Multivariate analyses showed that low pretreatment lymphocyte-to-monocyte ratio level, presence of pathological lymph node metastasis (ypN(+)), and high pretreatment serum C-reactive protein level were independent prognostic factors of overall survival and disease-free survival. In addition, time-to-event analysis divided into 2 groups by ypN status showed that low pretreatment lymphocyte-to-monocyte ratio was correlated with poor overall survival and disease-free survival not only in group ypN(-) but also in group ypN(+).
The present study had several limitations, including that it was a retrospective observational and single institutional study with Japanese patients.
The combination of lymphocyte-to-monocyte ratio and ypN status can be a predictive marker of poor prognosis and recurrence among patients with rectal cancer undergoing preoperative chemoradiotherapy. See Video Abstract at http://links.lww.com/DCR/A780.
尽管直肠癌的局部控制取得了进展,但远处器官复发仍是主要死亡原因之一。预后生物标志物对直肠癌患者的治疗具有重要价值。
本研究旨在探讨淋巴细胞与单核细胞比值对接受术前放化疗的直肠癌患者的预后影响,并阐明淋巴细胞与单核细胞比值的临床意义。
对前瞻性收集的直肠癌患者数据进行回顾性评估,以阐明淋巴细胞与单核细胞比值的临床相关性。
本研究在一个单一的专家中心进行。
本研究纳入了我院119例连续接受放化疗后行全直肠系膜切除术的直肠癌患者。8例因缺乏实验室数据被排除,最终111例患者纳入评估。
主要观察指标为淋巴细胞与单核细胞比值对接受放化疗的直肠癌患者的临床相关性。
放化疗的直肠癌患者中,治疗前淋巴细胞与单核细胞比值低的患者总生存期和无病生存期均显著较差。多因素分析显示,治疗前淋巴细胞与单核细胞比值低、病理淋巴结转移(ypN(+))、治疗前血清C反应蛋白水平高是总生存期和无病生存期的独立预后因素。此外,按ypN状态分为两组的事件发生时间分析显示,治疗前淋巴细胞与单核细胞比值低不仅与ypN(-)组的总生存期和无病生存期差相关,也与ypN(+)组相关。
本研究存在一些局限性,包括这是一项针对日本患者的回顾性观察性单机构研究。
淋巴细胞与单核细胞比值和ypN状态的联合可作为术前放化疗的直肠癌患者预后不良和复发的预测指标。见视频摘要:http://links.lww.com/DCR/A780 。